Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data Read more →
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal Read more →
Fierce Biotech Layoff Tracker 2026: Autolus decreases headcount by 13%; Replimune reduces staff Read more →
« All Events
February 4, 2025 @ 11:30 am
Presentations from the Olink team on the value of combining genomic and proteomic data for the best insights into human disease and development of new therapeutics, and more. After, enjoy lunch and networking.